Micko, a lot (not all) of the people on the KZA board are long term holders who have walked in the the valley of the shadow of death holding KZA for some time now. For example, my average buy in price is $0.40 and that is after first buying in at over $3 five years ago.
This is an oncology drug discovery company. Paxalisib , for all intents and purposes, is the only bullet in the gun. Either Paxalisib succeeds or Kazia fails. The question right now is what is the risk and the reward of Paxalisib succeeding versus failing DYOR.
